Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome

Int J Cardiol. 2016 May 1:210:1-3. doi: 10.1016/j.ijcard.2016.02.106. Epub 2016 Feb 15.
No abstract available

Keywords: Aquaporin-2; Diabetic nephropathy; Heart failure; Tolvaptan.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antidiuretic Hormone Receptor Antagonists / therapeutic use*
  • Aquaporin 2 / urine*
  • Benzazepines / therapeutic use*
  • Biomarkers / urine
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / urine*
  • Female
  • Heart Failure / complications
  • Heart Failure / drug therapy
  • Heart Failure / urine*
  • Humans
  • Nephrotic Syndrome / complications
  • Nephrotic Syndrome / drug therapy
  • Nephrotic Syndrome / urine*
  • Tolvaptan
  • Treatment Outcome

Substances

  • AQP2 protein, human
  • Antidiuretic Hormone Receptor Antagonists
  • Aquaporin 2
  • Benzazepines
  • Biomarkers
  • Tolvaptan